Sustainability Is the New Survival Strategy
Green issues shouldn’t be treated as “woke.” Instead, they should be seen as pharma’s license to operate. Three industry experts discuss.
False
Green issues shouldn’t be treated as “woke.” Instead, they should be seen as pharma’s license to operate. Three industry experts discuss.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
September 21, 2026
5 min read
From isotope supply to reimbursement, the practical challenges shaping real-world delivery in oncology
September 16, 2026
2 min read
Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies
September 16, 2026
2 min read
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
September 15, 2026
4 min read
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
False
Affiliations:
Specialties:
Areas of Expertise: